Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Beijing Double-Crane Pharmaceutical Launches Generic Lipid-Regulating Drug

This article was originally published in PharmAsia News

Executive Summary

Beijing Double-Crane Pharmaceutical recently launched its latest generic drug pitavastatin calcium for lipid regulation. This represents a significant milestone as it shows a Chinese pharmaceutical company has achieved the capability of developing and producing global-standard drug. Patented pitavastatin calcium was initially launched in Japan in 2003. Beijing Double-Crane received approval from China's State FDA for the generic drug in 2008, and it into large-scale production. Currently, the company's annual output of over 50 million tablets can meet domestic demand. Aiming to become a branded generic drug maker with international competency, Double-Crane has raised its overall quality management level by applying for cGMP authentication. (Click here for more - Chinese language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts